Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)

NCT03947255 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT03947255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03947255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 28, 2019
Completion date
November 6, 2022
Enrollment
12 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, hodgkin lymphoma, peripheral t cell lymphoma